Amneal EU was granted FDA orphan designation for hydroxocobalamin as a treatment of known or suspected cyanide poisoning, according to a post to the agency’s website.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals announces submission of BLA to U.S. FDA for XOLAIR
- Amneal Pharmaceuticals Positioned for Significant Growth with Strong Product Momentum and Strategic Advantages
- Amneal Pharmaceuticals receives FDA approval for bimatoprost ophthalmic solution
- Amneal Pharmaceuticals price target raised to $14 from $12 at JPMorgan
- Amneal Pharmaceuticals receives FDA approval of sodium oxybate oral solution